An open-label clinical trial of milnacipran in fibromyalgia syndrome with co-morbid depressive symptoms

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue 1, 2004, Pages 47-51

  Nagaoka, Shouhei ^a   Ohno, Mikako ^a   Sekiguchi, Akiko ^a  

^a Yokohama Minami Kyosai Hospital   (Japan)

Author keywords

Depression; Fibromyalgia syndrome; Milnacipran; Selective serotonin noradrenaline reuptake inhibitors

Indexed keywords

MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FIBROMYALGIA; HUMAN; MALE; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

EID: 1542514939     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500310004038     Document Type: Article

References (28)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of multicenter criteria committee. Arthritis Rheum 33: 160-72.
2. Kranzler JD, Gendreau JF, Rao SG (2002) The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 36: 165-213.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38: 19-27.
4. Carette S, McCain GA, Bell DA, Fam AG (1986) Evaluation of amytriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum 29: 655-9.
5. Goldenberg DL, Felson DT, Dinerman H (1986) A randomized, controlled trial of amytriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29: 1371-7.
6. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA (1988) A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis Rheum 31: 1535-42.
7. Carette J, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP et al (1994) Comparison of amytriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum 37: 32-40.
8. Geller SA (1989) Treatment of fibrositis with fluoxetine hydrochloride (Prozac). Am J Med 87: 594-5.
9. Wolfe F, Cathey MA, Hawley DJ (1994) A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23: 255-9.
10. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C (1996) A randomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39: 1852-9.
11. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr (2002) A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112: 191-7.
12. Anderberg UM, Marteinsdottir I, von Knorring L (2000) Citalopram in patients with fibromyalgia - a randomized, double-blind placebo-controlled study. Eur J Pain 4: 27-35.
13. Dwight MM, Arnold LM, O'Brien H, Metzger BS, Morris-Park E, Keck PE Jr (1998) An open trial of Venlafaxine treatment of fibromyalgia. Psychosomatics 39: 14-7.
14. Spencer CM, Wilde MI (1998) Milnacipran - a review of its use in depression. Drugs 56: 405-27.
15. Zung WWK (1965) A self-rating depression scale. Arch Gen Psychiatry 12: 63-70.
16. Zung WWK, Richards CB, Shrot MJ (1965) A self-rating depression scale in an outpatient clinic, further validation of the SDS. Arch Gen Psychiatry 13: 508-15.
17. Lorish CD, Maisiak R (1986) The face scale - a brief, non-verbal method for assessing patient mood. Arthritis Rheum 29: 906-9.
18. Yanus MB, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL (1981) Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11: 151-71.
19. Dailey PA, Bishop GD, Russell IJ, Fletcher EM (1990) Psychological stress and the fibrositis/fibromyalgia syndrome. J Rheumatol 17: 1380-5.
20. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA et al (1994) Hypothalamic-pitutary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37: 1583-92.
21. Hudson JI, Pope HG Jr (1996) The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin N Am 22: 285-303.
22. Katz RS, Kravitz HM (1996) Fibromyalgia, depression and alcoholism: a family history story. J Rheumatol 23: 149-54.
23. 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis sydrome. J Rheumatol 19: 104-9.
24. Russell IJ, Vaeroy H, Javors M, Nyberg F (1992) Cerebrospinal fluid biogenic amine metabolities in fibromyalgia/fibrositis sydrome and rheumatoid arthritis. Arthritis Rheum 35: 550-6.
25. Briley M (2003) New hope in the treatment of painful symptoms in depression. Curr Opin Invest Drugs 4: 42-5.
26. Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1: 277-99.
27. Kerns RD, Turk DC, Rudy TE (1985) The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 23: 345-56.
28. Cypress Bioscience (2002) Milnacipran significantly improves pain and fatigue in fibromyalgia patients. Press Release, Cypress Bioscience, San Diego, CA, USA http.//www.cypressbio.com/corp/news/press/releases/20021210.pdf